Why the study?
Does oral β-blocker treatment reduce all-cause mortality in contemporary post-myocardial infarction patients?
Population
Contemporary post-myocardial infarction patients (AMI survivors)
Design
Meta-analysis
Key result
Oral β-blocker treatment showed no association with all-cause mortality in contemporary post-myocardial infarction patients.
Authors
Loading...
Questions routine oral β-blocker use post-MI; challenges prior consensus and supports RCTs to clarify contemporary role.
Does oral β-blocker treatment reduce all-cause mortality in contemporary post-myocardial infarction patients?
This meta-analysis suggests that routine oral beta-blocker treatment may not reduce all-cause mortality in contemporary post-myocardial infarction patients, highlighting the need for large randomized clinical trials.
Aarvik et al. (2018) studied this question. Oral β-blocker treatment showed no association with all-cause mortality in contemporary post-myocardial infarction patients.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: